| Autor: |
Batinić J, Holik H, Vučinić Ljubičić I, Morić Perić M, Zekanović I, Berneš P, Romić I, Ivić M, Piršić M, Deak D, Rinčić G, Valković T, Radić Krišto D, Sertić D, Rončević P, Bašić-Kinda S |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Popis: |
Background: multiple myeloma (MM) still remains uncurable disease, despite recent therapeutical advancements, with multiple relapses and clone evolution leading to refractoriness. Thus there is still an unmet need for treatment options in these patients, especially those refractory to lenalidomide, one of which is pomalidomide. Aim: the aim of this analysis was to show real world data on treating multiple myeloma patients with relapsed/refractory (RR) disease with pomalidomde based combinations. Methods: We performed a retrospective analysis of outcomes of MM patients treated with pomalidomide in 7 Croatian hematology centres in the period between 2017 and 2019 (pomalidomide available and reimbursed since 2017). Results: we identified 31 patients with RR MM. Median age at start of pomalidomide treatment was 67 years (41 – 78). Median number of previous treatment lines was 4 (range 3 – 7). 14 (45%) patients underwent prior autologous stem cell transplantation (9 single, 5 tandem) and 1 patient allogeneic stem cell transplantation. All patients were exposed to bortezomib and lenalidomide before pomalidomide. Six patients were bortezomib refractory and 17 lenalidomide refractory. Patients were treated with pomalidomide in combination with dexamethasone alone (22 patients), with the addition of cyclophosphamide (8 patients) and in combination with PACE protocol (2 patients). 27 patients were evaluable: overall response rate (≥ PR) was 51% ; clinical benefit rate (≥ SD) was 55%. After median follow up of 12 months, median progression free survival was 6.8 months and median overall survival was 11.8 months. Anemia was reported in 54%, thrombocytopenia in 39% and neutropenia in 42% of patients. Only 5 patients had infective complications. 21 patients progressed and 15 patients died. Conclusion: this analysis confirms that in the setting of RR MM pomalidomide has limited efficacy with acceptable and manageable toxicities. Our data support previously reported clinical trials data, as well as real world data on pomalidomide. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
